Key Findings
The FDA issued finalized guidance on November 10, 2026, detailing the validation requirements for in vitro diagnostics used to detect pathogens during public health emergencies. These nonbinding recommendations apply to pre-EUA requests, EUA requests, and tests offered under enforcement discretion policies. The guidance specifically covers molecular and antigen tests for serious or life-threatening infectious diseases across CLIA-certified labs, point-of-care sites, and home use, though serology and antibody tests are excluded.
Technical Details
For viral nucleic acid tests using established technology, the FDA typically requires at least 30 positive and 30 negative specimens from the intended population. The agency emphasizes that smaller sets can be misleading, citing a case where a COVID-19 test’s positive percent agreement dropped from 100% to 71% after increasing the sample size from 12 to 24.
- Study Design: Prospective, all-comers studies with natural clinical specimens are preferred. In early outbreaks, archived or contrived samples may be used; synthetic RNA is preferred over synthetic DNA for RNA viruses.
- Analytical Sensitivity: The limit of detection is defined as the lowest concentration detected in 95% of replicates, confirmed by at least 20 replicates. Simulated matrices (e.g., clean transport media with mucin) are prohibited in these studies.
- Inclusivity: Molecular tests should generally show 100% nucleotide sequence identity via in silico analysis, with monthly evaluations for new mutations. A sensitivity drop of more than 3-fold for a variant requires risk analysis.
- Data Analysis: The FDA recommends calculating positive and negative percent agreement against a sensitive comparator using the Wilson Score method with 95% confidence intervals.
Background and Context
The guidance responds to assessments of the COVID-19 response, including a 2021 Booz Allen Hamilton report and a 2022 HHS Office of the Inspector General report. It clarifies that while the “may be effective” standard for EUAs allows lower evidence than full product approvals, all tests must be appropriately validated.
Significance and Outlook
Manufacturers can now develop change protocols for future modifications, such as adding new instruments, to avoid separate authorizations. Special considerations are provided for multi-analyte panels, which require validation for each analyte and cross-reactivity testing, and home-use tests, which must utilize noninvasive collection methods.
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime



